Conducting a quality study of the medicinal product - Vortioxetine

2023-509946-36-00 Protocol CBF23001 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 29 Jun 2024 · End 15 Aug 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CBF23001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 36
Countries 1
Sites 1

No therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adults

Key facts

Sponsor
CCDRD Cooperative Clinical Drug Research and Development AG, Biofarm Sp. z o.o.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
29 Jun 2024 → 15 Aug 2024
Decision date (initial)
2024-04-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adults

VersionLevelCodeTermSystem organ class
21.1 LLT 10081270 Major depressive disorder 10037175

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CCDRD Cooperative Clinical Drug Research and Development AG

Sponsor organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Address
Lindenallee 70, Dahlwitz-Hoppegarten Dahlwitz-Hoppegarten
City
Hoppegarten
Postcode
15366
Country
Germany

Scientific contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project Manager - CRO

Public contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project Manager - CRO

Biofarm Sp. z o.o.

Sponsor organisation
Biofarm Sp. z o.o.
Address
Ul. Walbrzyska 13
City
Poznan
Postcode
60-198
Country
Poland

Scientific contact point

Organisation
Biofarm Sp. z o.o.
Contact name
Ewa Puk, MSc, PhD

Public contact point

Organisation
Biofarm Sp. z o.o.
Contact name
Ewa Puk, MSc, PhD

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 36 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Ended
Diagnostic Consultative Centre Ascendent OOD
Bed Space for Short-term Stay, Ulitsa Bacho Kiro 47, 1202, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2024-06-29 2024-08-15 2024-06-29 2024-07-08

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-04 Bulgaria Acceptable
2024-02-21
2024-04-01
2 SUBSTANTIAL MODIFICATION SM-2 2024-06-05 Bulgaria Acceptable
2024-07-22
2024-07-29
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-07-29 Bulgaria 2024-07-29